CERTARA INC (CERT)
US15687V1098 - Common Stock
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list...
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance...
Certara to Participate in the Stephens Annual Investment Conference
Certara to Participate in the Stephens Annual Investment Conference
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that...
Certara Appoints John Reynders as New Independent Board Member
Certara Appoints John Reynders as New Independent Board Member
Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024. ...
MaxCyte Appoints Cynthia Collins to its Board of Directors
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it...
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.
Certara Completes Acquisition of Chemaxon
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry....
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. ...
Certara Becomes Oversold (CERT)
Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that...
Certara Launches Phoenix™ Version 8.5 Drug Development Software
Certara Launches Phoenix™ Version 8.5 Drug Development Software
Certara today announced the launch of Phoenix™ version 8.5 software, the pharmaceutical industry's gold standard in PK/PD modeling and simulation....
Certara Enters Oversold Territory (CERT)
CERT Stock Earnings: Certara Misses EPS, Misses Revenue for Q2 2024
CERT stock results show that Certara missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance...
Bullish Two Hundred Day Moving Average Cross - CERT
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it...
First Week of CERT February 2025 Options Trading
Certara Enters Oversold Territory (CERT)
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers....